460 Studies Now Enrolling
An Open Label Pilot Study of ACTH in the Treatment of IgA Nephropathy at high risk of progression
A study for patients with IgA nephropathy using doses of Acthar Gel (ACTH)
| Sponsor: | Mayo Clinic |
| Enrolling: | Male and Female Patients |
| IRB Number: | AAAP9821 |
| U.S. Govt. ID: | NCT02282930 |
| Contact: | Pietro Canetta: 212-305-0320 / pac2004@cumc.columbia.edu |
Additional Study Information:
The purpose of this study is to assess the most adequate dose of Acthar Gel (ACTH) in patients withIgA nephropathy. Acthar Gel (ACTH) has been approved by the Food and Drug Administration(FDA) for routine clinical use in the treatment of patients with proteinuria and patients withidiopathic nephrotic syndrome such as IgAN.
This study is closed
